Zealand Pharma's first phase III trial with dasiglucagon for the treatment of congenital hyperinsulinism did not reach its primary endpoint, according to a statement issued by the firm. The company is, however, pleased with some of the partial results in the study and looks forward to developing drugs for the disease going forward.
The firm currently awaits results coming from a different phase III trial involving the rare disease, which entails low blood sugar levels caused by abnormally high insulin levels in the blood. In this trial, dasiglucagon is tested on infants with congenital hyperinsulinism.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Hearing firms urge FDA to increase OTC safety requirements
A number of the world’s biggest hearing aid manufacturers have come together to encourage the US health authority to tighten the safety requirements for OTC hearing aids, which will hit the shelves in the US sometime this year.
Novo Nordisk launches oral semaglutide in India
Novo Nordisk’s diabetes drug, semaglutide, will be sold in the country in a similar price range as its injectable version.
Coloplast initiates trial of ostomy leakage product
The medtech company will being clinically testing its ostomy add-on product, Heylo, in January.
Top news from MedWatch this week
Miss anything?
Danish bank cuts Genmab price target, retains "buy" recommendation
Jyske Bank has adjusted its valuation of Genmab’s share price target to DKK 2850 (USD 434.4). Investors should continue to buy, the Danish bank says.
Senior Key Account Manager 
Principal Scientist 
Senior Director, Global Regulatory Lead 
Commercial Excellence Lead 
Senior Quality Assurance Consultant, Denmark 
NORDIC Medical Sales Director 
Lead Scientist, Global STA, Royal DSM/Glycom 
Senior Manager, Biostatistics 
Chemists are wanted for ALK's internal Aircraft Corps 
QA Specialist 
Associate Director, International Medical Affairs 
GxP QA Compliance Manager for Quality Assurance 
Health Economist 
QA Manager GMP/GDP Compliance & Audits